George Kemble compensation by year
Sagimet Biosciences Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $404,856 | $458,630 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $446,220 |
| Option awards | $129,713 | $0 |
| Non-equity incentive | $0 | — |
| Pension and deferred compensation | $0 | $0 |
| All other | $40,297 | $25,373 |
| Total | $574,866 | $930,223 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sagimet Biosciences Inc. DEF 14A filed April 18, 2024, accession 0001104659-24-048534, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Sagimet Biosciences Inc. filed document, accession 0001104659-24-048534. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 150,750 | $817,065 | — |
| Option | 142,544 | — | $6.36 |
| Option | 14,996 | — | $7.15 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Sagimet Biosciences Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Sagimet Biosciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| David Happel | President and Chief Executive Officer | $2,685,917 |
| Eduardo Martins | Chief Medical Officer | $1,509,081 |
| George Kemble · this page | Executive Chairman and former President, Chief Executive Officer and Chief Scientific Officer | $930,223 |
| Dennis Hom | Former Chief Financial Officer | $745,507 |
Board service
Sagimet Biosciences board · FY2024–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $45,726 | $129,864 | — | $0 | $175,590 |
| FY2024 | — | — | — | — | — |
Each year as the company reported it in Sagimet Biosciences's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Sagimet Biosciences pays directors a $40,000 cash retainer and $130,050 in Options. As stated in Sagimet Biosciences's FY2025 proxy.
The full Sagimet Biosciences compensation record
free company briefThis page is one person within Sagimet Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sagimet Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.